Press releases in 2003

23. 12. 2003 |
Slovene pharmaceutical company Lek d.d. has successfully defended its patent EP 1 095 037, which covers Lek’s synthesis of omeprazole before the Board of Appeal of the European Patent Office.
3. 12. 2003 |
Today, the Slovene Chamber of Commerce, bestowed the award of Innovator of the Year 2002 to a group composed of Dr. Viktor Menart and Mag. Simona Jevsevar from the Lek ...
25. 11. 2003 |
Ljubljana, 25 November 2003 – After the settlement signed in July of 2003 between GlaxoSmithKline PLC (GSK) and Novartis, including Lek d.d. Ljubljana, Lek Pharmaceuticals Inc. and Lek Services Inc., ...
15. 10. 2003 |
The pharmaceutical company Lek submitted adjusted prices for its leading products to the Agency for Medicinal Products of the Republic of Slovenia (the Agency). This will make it possible for ...
25. 9. 2003 |
Ljubljana, 25 September 2003 – After years of fruitful cooperation, the co-founders and co-shareholders of Bayer Pharma d.o.o. decided on ownership change in Joint Venture. Lek will support Bayer Pharma ...
3. 9. 2003 |
On Monday, 1 September 2003, the change of the company name and company headquarters of Lodz-based Argon SA was entered into the Court Register. The new name is: Lek SA ...
27. 8. 2003 |
On Monday, 25 August 2003, the President of the Polish Government, Mr Leszek Miller, visited Lek’s new plant, a Manufacturing and Logistics Centre in Strykow
21. 8. 2003 |
Novartis has taken a decision on Lek’s launching a generic omeprazole in the US market this week.
5. 8. 2003 |
We would like to inform you that the 19th General Meeting of Lek d.d. was held on Thursday, 31 July 2003, at the headquarters of Lek in Ljubljana, Verovškova 57.
18. 7. 2003 |
At the invitation of the company Lek d.d., Mr. Krzystof Makowski, Duke of the Polish Lodz region, came to visit Slovenia. During the visit, the Duke Makowski, accompanied by the ...
1. 7. 2003 |
After the company Novartis had entered into the ownership structure of Lek d.d., the 2nd meeting of Lek Supervisory Board was held on Friday, 27 June 2003 with new members. ...
30. 6. 2003 |
On the basis of the Statute of the joint-stock company Lek, we hereby convene the 19th General Meeting of Lek d.d. to be held on Thursday, 31 July 2003 at ...
16. 6. 2003 |
Following the cornerstone celebration at Lek’s Pharmaceutical Production and Logistics Centre in Stryków near Łódź in September last year, attended by Presidents Aleksander Kwaśniewski and Milan Kučan, investments works have ...
14. 4. 2003 |
Based on one reported case from a pharmacy, received on Friday, April 11, Lek Pharmaceuticals, d.d. is informing the public that there was a product mix-up in the packaging of ...
11. 4. 2003 |
A resolution on the ban on the distribution and use of the drug Dermo spray N, dermal spray produced by Lek d.d., was issued through the publication in the Official ...
28. 3. 2003 |
On Thursday, 27 March 2003, the newly appointed Supervisory Board of Lek Pharmaceuticals d.d. held its first meeting. The composition of the Supervisory Board reflects the changes in the ownership ...
19. 3. 2003 |
The year 2002 was a major turning point for Lek – the takeover by the Swiss firm Servipharm AG, which is 100% owned by Novartis Pharma AG, was completed.
4. 2. 2003 |
Lek Pharmaceuticals d.d., Verovškova 57, Ljubljana, hereby announces that
4. 2. 2003 |
A Slovenian pharmaceutical company, Lek Pharmaceuticals d.d., was granted by the US Food and Drug Administration (FDA) a final approval for the marketing of 10 and 20mg omeprazol capsules. The ...
21. 1. 2003 |
Lek Pharmaceuticals d.d. hereby announces that they have issued, in accordance with Article 66 of the Act on Medicinal Products and Medical Devices, a written notification to wholesale drugstores, to ...
20. 1. 2003 |
Lek Pharmaceuticals d.d., Verovškova 57, Ljubljana, hereby announces that at the 18th General Meeting of the joint-stock company, held on 20 January 2003, Lek shareholders discussed and adopted the following ...
6. 1. 2003 |
Ljubljana, January 6, 2003 – Lek d.d, a Slovene pharmaceutical company, has entered the world’s largest pharmaceuticals market with its leading product, co-amoxiclav. By entering the U.S. market, Lek has, ...